REG - Destiny Pharma PLC - Grant from the Cystic Fibrosis Foundation

Destiny PharmaAnnouncement

12/07/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220712:nRSL0777Sa&default-theme=true

RNS Number : 0777S  Destiny Pharma PLC  12 July 2022

Destiny Pharma plc

("Destiny Pharma" or "the Company")

 

Destiny Pharma receives award from the Cystic Fibrosis Foundation

 

Study to investigate potential of XF-73 to treat MRSA infection in people with
cystic fibrosis

 

Brighton, United Kingdom - 12 July 2022 - Destiny Pharma plc (AIM: DEST), a
clinical stage biotechnology company focused on the development of novel,
hospital infection prevention and treatment products that address the global
challenge of antimicrobial resistance (AMR), today announces it has received
an award from the Cystic Fibrosis Foundation. The research project will
establish the potential of the Company's proprietary XF-73 drug as a novel
treatment for cystic fibrosis patients infected with methicillin-resistant
Staphylococcus aureus (MRSA). The project will have access to clinical
isolates collected from people with cystic fibrosis and the work will be
carried out by experienced researchers associated with the Foundation.
Financial terms of the collaboration have not been disclosed.

 

Neil Clark, Chief Executive Officer of Destiny Pharma, stated: "We are very
excited to carry out this project with the Cystic Fibrosis Foundation. The
tailored research will allow us to demonstrate the potential of XF-73 in
alleviating the suffering of thousands of MRSA-infected cystic fibrosis
patients and is another programme derived from our proprietary XF platform."

 

Cystic fibrosis (CF) is a progressive, genetic disease that causes persistent
lung infections and limits the ability to breathe. It is estimated that over
70,000 people worldwide are living with CF, with more than 30,000 in the US
alone, and approximately 1,000 new cases diagnosed each year 1  (#_ftn1) .

 

MRSA is becoming more common among the pathogenic bacteria that cause lung
infections in CF patients, having a presence in about 25% of people with the
disease 2  (#_ftn2) .

 

MRSA is resistant to multiple antibiotics -- biofilms are thought to be
involved and lung infections caused by the bacteria often become long-term(3).
MRSA produces several virulence factors and its presence in the respiratory
tract is associated with significant lung damage and is a major cause of
mortality. The ability to treat such MRSA infections effectively would
therefore significantly help CF patients.

 

Destiny Pharma's lead compound, XF-73, is being prepared for Phase 3 clinical
development to prevent post-surgical Staphylococcal infections. To date, XF-73
has demonstrated in vitro to be active against many of the world's most
pathogenic bacteria as outlined in the WHO priority list(4). XF-73 acts via an
ultra-rapid action, which kills bacteria (including antibiotic resistant
strains), leaving them unable to mount a resistance response, according to
Professor MacLean, Oxford University.(5) To date, no existing antibiotic
resistance mechanism has been identified which confers resistance to XF-73.
The spectrum of activity, the absence of an identified resistance mechanism
and the ability to maintain its activity within biofilms puts XF-73 in a
unique position to address important challenges posed by antimicrobial
resistance (AMR).

 

 

For further information, please contact:

 

Destiny Pharma plc
Neil Clark, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440
pressoffice@destinypharma.com
(https://www.destinypharma.com/2022/05/26/26-may-2022-destiny-pharma-plc-board-changes/blank)

 

Optimum Strategic Communications
(https://www.destinypharma.com/2022/05/26/26-may-2022-destiny-pharma-plc-board-changes/blank)

Mary Clark / Manel Mateus / Eleanor Cooper

+44 (0) 203 922 0891
DestinyPharma@optimumcomms.com
(https://www.destinypharma.com/2022/05/26/26-may-2022-destiny-pharma-plc-board-changes/blank)

 

finnCap Ltd (Nominated Advisor and Broker)
Geoff Nash / Kate Bannatyne / George Dollemore, Corporate Finance

Alice Lane / Nigel Birks / Harriet Ward, ECM

+44 (0) 207 220 0500

 

MC Services AG
Anne Hennecke / Andreas Burckhardt

+49-211-529252-12

 

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused
on the development of novel medicines that can prevent life-threatening
infections. Its pipeline has novel microbiome-based biotherapeutics and XF
drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the
prevention of C. difficile infection (CDI) recurrence which is the leading
cause of hospital acquired infection in the US and also XF-73 nasal gel, which
has recently completed a positive Phase 2b clinical trial targeting the
prevention of post-surgical staphylococcal hospital infections including MRSA.
It is also co-developing SPOR-COV(TM), a novel, biotherapeutic product for the
prevention of COVID-19 and other viral respiratory infections and has earlier
grant funded XF drug research projects.

For further information on the company, please visit www.destinypharma.com
(https://www.destinypharma.com)

 

 

 

 

 1  (#_ftnref1) https://www.cff.org/intro-cf/about-cystic-fibrosis
(https://www.cff.org/intro-cf/about-cystic-fibrosis)

 2  (#_ftnref2)
https://www.cff.org/managing-cf/methicillin-resistant-staphylococcus-aureus-mrsa
(https://www.cff.org/managing-cf/methicillin-resistant-staphylococcus-aureus-mrsa)

(3)
https://www.postersessiononline.eu/173580348_eu/congresos/ECFS2021/aula/-EPS3_9_ECFS2021.pdf

(4)
https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed
(https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed)

(5) R. Craig MacLean, Assessing the Potential for Staphylococcus aureus to
Evolve Resistance to XF-73. Trends in Microbiology, (2020), 1812.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCRBMFTMTMBBFT